Acadia Pharmaceuticals (ACAD) Profit After Tax Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.49% |
| Dec 31, 2025 | 43.56% |
| Sep 30, 2025 | 23.28% |
| Jun 30, 2025 | 21.36% |
| Mar 31, 2025 | 17.25% |
| Dec 31, 2024 | 36.34% |
| Sep 30, 2024 | 22.69% |
| Jun 30, 2024 | 21.13% |
| Mar 31, 2024 | 17.02% |
| Dec 31, 2023 | 21.97% |
| Sep 30, 2023 | -0.96% |
| Jun 30, 2023 | 15.07% |
| Mar 31, 2023 | 4.55% |
| Dec 31, 2022 | 9.54% |
| Sep 30, 2022 | 16.06% |
| Jun 30, 2022 | 12.80% |
| Mar 31, 2022 | -5.18% |
| Dec 31, 2021 | 11.35% |
| Sep 30, 2021 | 27.39% |
| Jun 30, 2021 | 9.26% |
| Mar 31, 2021 | -5.95% |
| Dec 31, 2020 | -7.84% |
| Sep 30, 2020 | -16.82% |
| Jun 30, 2020 | -1.37% |
| Mar 31, 2020 | -16.87% |
| Dec 31, 2019 | -13.33% |
| Sep 30, 2019 | -11.11% |
| Jun 30, 2019 | -20.65% |
| Mar 31, 2019 | -36.76% |
| Dec 31, 2018 | -40.30% |
| Sep 30, 2018 | -42.18% |
| Jun 30, 2018 | -47.44% |
| Mar 31, 2018 | -54.73% |
| Dec 31, 2017 | -58.85% |
| Sep 30, 2017 | -93.55% |
| Jun 30, 2017 | -65.58% |
| Mar 31, 2017 | -69.83% |
| Dec 31, 2016 | -71.53% |
| Sep 30, 2016 | -69.78% |
| Jun 30, 2016 | -61.18% |
| Mar 31, 2016 | -53.53% |
| Dec 31, 2015 | -28.99% |
| Sep 30, 2015 | -55.88% |